Pfizer beats forecasts as oncology drugs grow
July 29 (Reuters) - Pfizer Inc, which in May officially abandoned its bid to buy British rival AstraZeneca Plc, reported higher-than-expected second-quarter earnings, helped by growing sales of its cancer medicines.
The largest U.S. drugmaker on Tuesday said it had earned $2.91 billion, or 45 cents per share. That compared with $14.1 billion, or $1.98 per share, a year earlier, when Pfizer received more than $10 billion in proceeds from the spinoff of its animal health business into a new publicly traded company, Zoetis.
Excluding special items, Pfizer earned 58 cents per share. Analysts on average expected 57 cents, according to Thomson Reuters I/B/E/S. (Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)
- Alabama man gets $1,000 in police settlement, his lawyers get $459,000
- Probe: Athletes took fake classes at University of North Carolina
- Canada's Harper vows tighter security after Parliament attack |
- Some U.S. hospitals weigh withholding care to Ebola patients
- Man arrested after jumping White House fence, causing lockdown